ID   Mo
AC   CVCL_1439
SY   MO; Mo-T; Mo T; MoT; MOT
DR   BTO; BTO:0001014
DR   CLO; CLO_0007815
DR   CLO; CLO_0037184
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-8066
DR   BioSample; SAMN03471131
DR   cancercelllines; CVCL_1439
DR   Cell_Model_Passport; SIDM00623
DR   ChEMBL-Cells; CHEMBL3308631
DR   ChEMBL-Targets; CHEMBL614722
DR   Cosmic; 683660
DR   Cosmic; 908149
DR   Cosmic; 1120712
DR   Cosmic-CLP; 908149
DR   DepMap; ACH-002339
DR   EGA; EGAS00001000978
DR   GDSC; 908149
DR   GEO; GSM1670121
DR   GEO; GSM1670131
DR   IARC_TP53; 21525
DR   LINCS_LDP; LCL-1096
DR   Lonza; 1308
DR   PharmacoDB; MoT_947_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1439
DR   Wikidata; Q54906275
RX   CelloPub=CLPUB00468;
RX   Patent=US4438032;
RX   PubMed=305224;
RX   PubMed=6600440;
RX   PubMed=6981847;
RX   PubMed=6984393;
RX   PubMed=6987658;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://en.wikipedia.org/wiki/Moore_v._Regents_of_the_University_of_California
WW   https://scocal.stanford.edu/opinion/moore-v-regents-university-california-31115
WW   http://www.bio.davidson.edu/people/kabernd/Indep/carainbow/Cells.htm
WW   http://www.wipo.int/wipo_magazine/en/2006/05/article_0008.html
WW   http://helatermproject.blogspot.ch/2012/03/john-moore.html
CC   Group: Patented cell line.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8066.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Transformant: NCBI_TaxID; 11909; Human T-lymphotropic virus 2 (HTLV-2).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.37%; East Asian, North=0%; East Asian, South=1.84%; South Asian=0.34%; European, North=68.22%; European, South=29.24% (PubMed=30894373).
CC   Anecdotal: John Moore, the patient from which this cell line is derived, sued David Golde and the University of California over the patent that they deposited on the Mo cell line. Although his claims of ownership were rejected, his physician was deemed to have breached his fiduciary duty by not informing Moore of the economic and financial interests arising from the derivation of the cell line.
CC   Derived from site: In situ; Spleen; UBERON=UBERON_0002106.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): ATCC; Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 9,13
ST   D16S539: 11
ST   D5S818: 11,12
ST   D7S820: 9,12
ST   TH01: 9.3
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C7402; Hairy cell leukemia
DI   ORDO; Orphanet_58017; Classic hairy cell leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2302 ! Mo-B
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 35
//
RX   CelloPub=CLPUB00468;
RA   Javitt G.H.;
RT   "Why not take all of me? Reflections on the immortal life of Henrietta
RT   Lacks and the status of participants in research using human
RT   specimens.";
RL   Minn. J. Law Sci. Technol. 11:713-755(2010).
//
RX   Patent=US4438032;
RA   Golde D.W., Quan S.G.;
RT   "Unique T-lymphocyte line and products derived therefrom.";
RL   Patent number US4438032, 20-Mar-1984.
//
RX   PubMed=305224; DOI=10.7326/0003-4819-88-3-323;
RA   Saxon A., Stevens R.H., Golde D.W.;
RT   "T-lymphocyte variant of hairy-cell leukemia.";
RL   Ann. Intern. Med. 88:323-326(1978).
//
RX   PubMed=6600440; DOI=10.1007/BF02617996;
RA   Uittenbogaart C.H., Cantor Y., Fahey J.L.;
RT   "Growth of human malignant lymphoid cell lines in serum-free medium.";
RL   In Vitro 19:67-72(1983).
//
RX   PubMed=6981847; DOI=10.1126/science.6981847;
RA   Kalyanaraman V.S., Sarngadharan M.G., Robert-Guroff M., Miyoshi I.,
RA   Golde D.W., Gallo R.C.;
RT   "A new subtype of human T-cell leukemia virus (HTLV-II) associated
RT   with a T-cell variant of hairy cell leukemia.";
RL   Science 218:571-573(1982).
//
RX   PubMed=6984393;
RA   Gauwerky C.E., Lusis A.J., Golde D.W.;
RT   "Erythroid-potentiating activity: characterization and target cells.";
RL   Exp. Hematol. 8 Suppl. 8:117-127(1980).
//
RX   PubMed=6987658; DOI=10.1073/pnas.77.1.593;
RA   Golde D.W., Bersch N., Quan S.G., Lusis A.J.;
RT   "Production of erythroid-potentiating activity by a human
RT   T-lymphoblast cell line.";
RL   Proc. Natl. Acad. Sci. U.S.A. 77:593-596(1980).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//